Carna Biosciences, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019
For full year ending December 31, 2019, the consolidated company expects net sales of JPY 1,240 million, operating loss of JPY 1,658 million, loss attributable to owners of parent of JPY 1,693 million or JPY 166.03 per share.